All News
Hydroxychloro-King (3.7.2025)
Dr. Jack Cush reviews the news, journal reports and regulatory actions from the past week on RheumNow.com
Read Article
MMWR: Idiopathic Pulmonary Fibrosis Mortality in the United States
d
MMWR
Idiopathic pulmonary fibrosis (IPF), a progressive lung disease characterized by scarring and worsening lung function, has a poor prognosis. An estimated 21% of IPF deaths might be attributable to occupational exposures.
ED Utilization by Psoriatic and Spondyloarthritis Patients
A cohort analysis of ambulatory emergency department (ED) utilization by patients with psoriatic arthritis (PsA) and radiographic axial spondyloarthritis (r-axSpA) demonstrated significant use for less urgent and nonurgent health issues, particularly in rural settings.
A Review of Relapsing Polychondritis
A current review in the Journal of Thoracic Disease on relapsing polychondritis (RP), suggests that while this rare disorder may have an uncertain pathogenesis, its diagnosis and therapeutical management has improved.
Read Article
Crohn’s Microbiome may Predispose to Axial Spondyloarthritis
d
EurekAlert!
People with Crohn’s disease and related joint inflammation linked to immune system dysfunction have distinct gut bacteria or microbiota, with the bacterium Mediterraneibacter gnavus being a potential biomarker, according to new study by Weill Cornell Medicine researchers.
Read Article
An Unusual Consult for Myopathy
Presentation by Dr. Kelsey Lemmen, at the Rheumatology Winter Clinical Symposia - Feb 2025
https://t.co/DYlzee6qcs https://t.co/nUxTC9roF9
Dr. John Cush RheumNow ( View Tweet)
A Review of Relapsing Polychondritis
A current review in the Journal of Thoracic Disease on relapsing polychondritis (RP), suggests that while this rare disorder may have an uncertain pathogenesis, its diagnosis and therapeutical management has improved.… https://t.co/keacvqjlU7 https://t.co/TkYwNnYtxF
Dr. John Cush RheumNow ( View Tweet)
Crohn’s Microbiome may Predispose to Axial Spondyloarthritis
Researchers at Weill Cornell Medicine found that people with Crohn’s disease and related joint inflammation have distinct gut bacteria, with Mediterraneibacter gnavus as a potential biomarker.
https://t.co/SI03wAJ3UU https://t.co/dlt3VxBDLw
Dr. John Cush RheumNow ( View Tweet)
CDC: More women (25.4%) than men (23.2%) had chronic pain in last 3 mos, Esp in large central metropolitan areas(22% vs 19%, F>M). For both recent chronic pain increased with decreasing urbanicity. https://t.co/rDsCQWvAae https://t.co/mhczpWFsdw
Dr. John Cush RheumNow ( View Tweet)
Neuropsychiatric Lupus: More than just a headache
Presentation by Dr. Daniel Carlson, at the Rheumatology Winter Clinical Symposia - Feb 2025
https://t.co/v0da4UNFNV https://t.co/BhBKOgak4W
Dr. John Cush RheumNow ( View Tweet)
Normalizing Serologies Enhances Remission in SLE
Analysis of five phase III belimumab (BEL) trials reveals that normalizing serologies affords protection against severe and renal SLE flares, supporting the concept of treat-to-target to minimize risk in SLE.… https://t.co/eW9EUyvts7 https://t.co/OdM0WkLtjd
Dr. John Cush RheumNow ( View Tweet)
Intraarticular Steroids in OA Lowers Need for Pain Meds
Is it possible that intra-articular corticosteroid injections for osteoarthritis might affect the use of opioids?
https://t.co/pw6vWbFRQx https://t.co/5KrB9uJv7M
Dr. John Cush RheumNow ( View Tweet)
Genentech announced that FDA has accepted a Supplemental Biologics License Application for obinutuzumab (anti-CD20 mAb; Gazyva) for the Treatment of Lupus Nephritis based on positive results from Phase III REGENCY study. FDA decision by October 2025 https://t.co/Mx3YDUfkMg https://t.co/MTBZo1TCrK
Dr. John Cush RheumNow ( View Tweet)
Sleep disturbance increases disability progression - Prospective cohort data from from 70K Nurses’ Health Study w/ 392 having MS, 7,302 DM, & 25K OA. Having Sleep apnea or disturbances signif incr disability in OA & DM (OR~1.4) as was excessive daytime sleepiness… https://t.co/5PP18gqDqi https://t.co/u1HFOstv8W
Dr. John Cush RheumNow ( View Tweet)
FDA grants priority reviews to:
- Nicalizumab (J&J; FcRn antibody) for use in Myasthenia gravis.
- Upadacitinib (AbbVie; JAK inhib) for use in GCA
- Namistat (BI: PDE4B inhib) for use in Idiopathic pulmonary fibrosis
- Inalizumab (Hansen; anti-CD19) for use in IG4 rel Dz
-… https://t.co/dsg9vZASrk https://t.co/8t2USASmm8
Dr. John Cush RheumNow ( View Tweet)
SOCS1 Insufficiency - a Rare Inborn Error of Immunity
Lancet Rheumatology has published a population study of the rare suppressor of cytokine signalling 1 (SOCS1) insufficiency - an inborn error of immunity affecting the negative regulation of cytokine and growth factor… https://t.co/I0muoIk5GL https://t.co/jbcuAZivci
Dr. John Cush RheumNow ( View Tweet)
Early Hydroxychloroquine Slows Cutaneous Lupus Progression
A prospective study of patients with limited cutaneous lupus erythematosus (CLE) shows that early introduction of hydroxychloroquine (HCQ) may prevent progression to systemic lupus erythematosus (SLE).… https://t.co/cxz4DJ6AUs https://t.co/FlgwykFnfl
Dr. John Cush RheumNow ( View Tweet)
Bimekizumab efficacy and safety in patients with psoriatic arthritis who had skin and nail psoriasis at baseline: Up to 2-year results from two phase 3 studies
https://t.co/RZSwrj8as8
Dr. John Cush RheumNow ( View Tweet)
RheumNow Live 2025 is now available On Demand
For the first time, https://t.co/4UQlqwujiR is offering exclusive access to:
✅ 7 STEP Talks from top rheumatology experts
✅ 21 Powerful lectures and Q & A Panels answering real-world questions
✅ All speaker slides and handouts… https://t.co/HokIfxbgTd https://t.co/ztVymFLuRT
Links:
Dr. John Cush RheumNow ( View Tweet)
From Bellyache to Bloodstorm - a Mesenteric Sclerosis case with Macrophage Activation Syndrome
Presentation by Dr. Anjali Nidhaan at the Rheumatology Winter Clinical Symposia - Feb 2025
https://t.co/pXwav5f2BI https://t.co/0Faao7zhbV
Dr. John Cush RheumNow ( View Tweet)